Key Points
- EVP Murdo Gordon sold 6,879 shares of Amgen on November 12 at an average price of $336.83 for about $2.32 million, reducing his ownership by 14.1% to 41,923 shares, per an SEC filing.
- Amgen beat quarterly expectations, reporting EPS of $5.64 (vs. $5.01 expected) and revenue of $9.56 billion (+12.4% YoY), and issued FY 2025 EPS guidance of 20.60–21.40.
- Quarterly dividend announced: $2.38 (ex-dividend Nov 21, payable Dec 12), which annualizes to $9.52 and implies a roughly 2.8% yield.
Amgen Inc. (NASDAQ:AMGN - Get Free Report) SVP Rachna Khosla sold 890 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company's stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Amgen Stock Performance
Shares of NASDAQ AMGN traded down $3.95 during trading hours on Friday, hitting $332.05. 522,278 shares of the company's stock were exchanged, compared to its average volume of 2,731,422. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $345.84. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The stock has a market capitalization of $178.80 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 2.61 and a beta of 0.45. The company's 50-day moving average price is $293.85 and its 200-day moving average price is $290.01.
Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion during the quarter, compared to analysts' expectations of $8.98 billion. During the same period in the prior year, the company earned $5.58 EPS. The business's quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.
Amgen Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, November 21st. Amgen's payout ratio is currently 73.57%.
Hedge Funds Weigh In On Amgen
Several institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Abel Hall LLC bought a new position in shares of Amgen in the first quarter valued at about $232,000. OVERSEA CHINESE BANKING Corp Ltd lifted its position in Amgen by 48.9% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,254 shares of the medical research company's stock worth $391,000 after buying an additional 412 shares in the last quarter. Larson Financial Group LLC grew its holdings in Amgen by 248.0% during the 1st quarter. Larson Financial Group LLC now owns 3,616 shares of the medical research company's stock worth $1,127,000 after acquiring an additional 2,577 shares during the last quarter. Finally, Bridgewater Advisors Inc. acquired a new stake in Amgen in the 1st quarter valued at about $695,000. 76.50% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. Deutsche Bank Aktiengesellschaft raised their price objective on Amgen from $280.00 to $285.00 and gave the stock a "hold" rating in a research report on Tuesday. Bank of America raised their target price on Amgen from $261.00 to $272.00 and gave the stock an "underperform" rating in a research report on Friday, September 26th. The Goldman Sachs Group lowered their price target on shares of Amgen from $405.00 to $400.00 and set a "buy" rating on the stock in a report on Wednesday, November 5th. DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a report on Monday. Finally, Piper Sandler lifted their target price on shares of Amgen from $342.00 to $381.00 and gave the company an "overweight" rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Amgen currently has an average rating of "Hold" and a consensus price target of $314.05.
View Our Latest Stock Analysis on AMGN
About Amgen
(
Get Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
